Skip to main content
SpringerLink
Log in

Effect of cyclodextrins on lonidamine release and in-vitro cytotoxicity

  • Original Article
  • Published:
Journal of Inclusion Phenomena and Macrocyclic Chemistry Aims and scope Submit manuscript

Abstract

The objective of this work was to study the effect of natural, hydroxypropyl and partially methylated cyclodextrins on the solubility of lonidamine and the cytotoxicity of the inclusion complex. The solubility study was conducted according to Higuchi et al. where HP-α-CD, HP-β-CD and HP-γ-CD showed type AL solubility curves indicating the formation of inclusion complexes with molar ratio of 1:1 with lonidamine. However, AP and AN type phase solubility behaviors were observed with PM-CD and α-CD, β-CD and γ-CD, respectively. Solubility enhancement factors and stability constants (K1:1 and K1:2) were calculated from the phase diagrams as appropriate. The characterization of the above inclusion complexes was evaluated using differential scanning calorimetry, Fourier transform infrared, and dissolution. Lonidamine solubility was improved with all tested cyclodextrins and specifically with PM-β-CD (1148 mg/L) where the solubility increased by 380-fold compare to its solubility in water (3 mg/L) leading to a fast dissolution rate of the latter in less than 3 min. In addition, the in-vitro cytotoxicity studies showed a modest increase in the cytotoxicity of lonidamine complex with CD against the human glioblastoma cell line SNB-19. Cyclodextrins could be useful to improve the solubility of lonidamine and hence its bioavailability, which is a drug of interest in the cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Shevchuk, I., Chekulayev, V., Moan, J., Berg, K.: Effects of the inhibitors of energy metabolism, lonidamine and levamisole, on 5-aminolevulinic-acid-induced photochemotherapy. Int. J. Cancer 67, 791–799 (1996)

    Article  CAS  Google Scholar 

  2. Pratesi, G., De Cesare, M., Zumino, F.: Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft. Cancer Chemother. Pharmacol. 38, 123–128 (1996)

    Article  CAS  Google Scholar 

  3. Dogliotti, L., Berrtui, A., Buniva, T., Zola, P., Bau, M.G., Farris, A., Sarobba, M.G., Bottini, A., Alquati, P., Deltetto, F., Gosso, P., Monzeglio, C., Moro, G., Sussio, M., Perroni, D.: Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J. Clin. Oncol. 14, 1165–1172 (1996)

    CAS  Google Scholar 

  4. Zaniboni, A., Meriggi, F., Alghisi, A., Mutti, S., Distefano, L., Bettini, L., Simoncini E., Marpicati, P., Montini E.: Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: a phase II study. Cancer J 81, 435–437 (1995)

    CAS  Google Scholar 

  5. Gardin, G.: Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. Eur. J. Cancer Part A 32A, 176–177 (1996)

    Article  CAS  Google Scholar 

  6. Fanciulli, M.: Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Oncol. Res. 8, 111–120 (1996)

    CAS  Google Scholar 

  7. Gadducci, A., Brunetti, I., Muttini, M.P., Fanucchi, A., Dargenio, F., Giannessi, P.G., Conte, P.F.: Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 30(2), 1432–1435 (1994)

    Article  CAS  Google Scholar 

  8. Lahiani-Skiba, M., Boulet, Y., Youm, I., Bounoure, F., Vérite, Ph., Arnaud, Ph., Skiba, M.: Improvement in the water solubility and stability of 4ASA by the use of cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 57, 211–217 (2007)

    Article  CAS  Google Scholar 

  9. Palmieri, G.F., Wehrlé, P., Martelli, S.: Interactions between Lonidamine and beta-or hydroxypropyl-beta-cyclodextrin. Drug. Dev. Ind. Pharm 24(7), 653–660 (1998)

    Article  CAS  Google Scholar 

  10. Higuchi, T., Connors, K.A.: Preparation and evaluation of ketoconazole-[beta]-cyclodextrin. Anal. Chem. Instrum. 4, 117–212 (1965)

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Pharmacie Galénique, University of Rouen, 22 Bd Gambetta, Rouen, 76000, France

    M. Lahiani-Skiba, F. Bounoure & M. Skiba

  2. Laboratoire d’Automatique et de génie des procédés, (LAGEP) UMR-CNRS 5007, CPE Lyon, 69622, France

    M. Lahiani-Skiba, F. Bounoure, H. Fessi & M. Skiba

  3. Laboratoire de Pharmacie Galénique, UFR Médecine-Pharmacie, 22 Bd Gambetta, Rouen, 76183, France

    M. Skiba

Authors
  1. M. Lahiani-Skiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Bounoure
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Fessi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Skiba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Skiba.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lahiani-Skiba, M., Bounoure, F., Fessi, H. et al. Effect of cyclodextrins on lonidamine release and in-vitro cytotoxicity. J Incl Phenom Macrocycl Chem 69, 481–485 (2011). https://doi.org/10.1007/s10847-010-9872-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10847-010-9872-7

Keywords

Search

Navigation